Allergy immunotherapy (sublingual allergen extracts) coverage criteria
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guideline for specific FDA‑approved allergen immunotherapy products (Grastek, Odactra, Oralair, Ragwitek) governing initial authorization and reauthorization criteria for CareOregon members.
No material clinical or coverage changes in this revision.
Coverage Criteria for SLIT Products
Initial Authorization Criteria
Covered when ALL of the following are met:
Clinical branches (meet either 2.1 OR 2.2)
2.1 Asthma branch
- 2.1.1 Diagnosis of asthma.
- 2.1.2 Trial and failure, or contraindication to, an inhaled corticosteroid.
2.2 Pediatric impact branch
- 2.2.1 Patient is less than 21 years of age.
- 2.2.2 Submission of medical records (e.g., chart notes) confirming the condition impacts the patient's health (examples: quality of life, function, growth, development, ability to participate in school, perform activities of daily living).
Medical records required to demonstrate impact for patients <21 years.
Reauthorization
Reauthorization
Approval length for reauthorization is 12 months; guideline type is Prior Authorization.
Provider Requirements and Documentation
Prior authorization required for Grastek, Odactra, Oralair, Ragwitek
Prior authorization is required for the listed sublingual immunotherapy (SLIT) products: Grastek, Odactra, Oralair, and Ragwitek. Approvals are issued for 12 months and apply to both initial authorization and reauthorization when criteria are met. This PA guideline governs these specific FDA‑approved oral allergen immunotherapy products.
Document required prior therapy trials (inhaled corticosteroid, antihistamines, nasal corticosteroids)
Prior to approval, document a trial and failure of required therapies: for patients with asthma, a trial and failure (or documented contraindication) of an inhaled corticosteroid is required; all patients must have trial and failure with oral antihistamines and nasal corticosteroids.
- Asthma branch: trial and failure, or contraindication to, an inhaled corticosteroid (2.1.2).
- All patients: trial and failure with oral antihistamines and nasal corticosteroids (criterion 3).
Submit medical records to demonstrate pediatric impact
When the approval pathway relies on pediatric impact (patients <21 years), submit supporting medical records such as chart notes that confirm the condition significantly impacts the patient’s health (examples include effects on quality of life, function, growth, development, school participation, or activities of daily living).
- Applicable when patient is less than 21 years of age (criterion 2.2.1).
- Provide chart notes or other medical records demonstrating impact on health/function (criterion 2.2.2).
Denial triggers when required criteria or documentation are missing
Requests may be denied if the documented approval criteria are not met. Common denial triggers include lack of FDA approval for the treated condition, absence of skin test or serologic evidence of IgE sensitization to the allergen, or missing documentation of required prior therapy trials.
- Requested drug must be FDA‑approved for the condition (criterion 1).
- Missing skin test and/or serologic evidence of IgE antibodies to the allergen (criterion 4).
- No documentation of trial and failure (or contraindication) of inhaled corticosteroid for asthma or of oral antihistamines and nasal corticosteroids (criteria 2.1.2 and 3).
- Absence of prescribing by or consultation with an allergist or immunologist (criterion 6) may contribute to denial.
Key Definitions
Background
This policy covers FDA‑approved oral allergen immunotherapy tablets — specifically Grastek, Odactra, Oralair, and Ragwitek — and establishes the clinical and documentation requirements needed to determine medical necessity for initiation and continuation of these therapies. The guideline is a prior authorization policy and applies to both initial authorization and reauthorization, with approvals issued for 12 months when criteria are met.
Approval for therapy requires that the requested drug is FDA‑approved for the condition and that additional clinical conditions are satisfied. These include either an asthma branch (a diagnosis of asthma plus trial and failure, or contraindication to, an inhaled corticosteroid) or a pediatric branch (patient <21 years with submission of medical records showing the condition impacts health). All authorizations also require trial and failure with oral antihistamines and nasal corticosteroids, evidence of IgE sensitization by skin test or serology, demonstrated efficacy of the requested drug for the specific allergen, and that the medication be prescribed by or in consultation with an allergist or immunologist.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.